NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments

Adjustments have no impact on cash and cash equivalents, cash runway, or business operations. Restatement is expected to reduce previously reported stock-based compensation expense, warrant liabilities, and accumulated deficit. VANCOUVER, British Columbia, Sept. 25, 2026 (GLOBE NEWSWIRE) — NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) […]